Importantly, results derived from these cellular and animal models could be further extended by the evaluation of the TDP-43 protein level in plasma extracellular vesicles (EVs) from the bulbar-onset ALS patient enrolled in Phase II clinical trial (NCT05508074). Here, TARDBP is linked to amyotrophic lateral sclerosis.